BioLineRx Statistics
Share Statistics
BioLineRx has 3.72M
shares outstanding. The number of shares has increased by 74.04%
in one year.
| Shares Outstanding | 3.72M |
| Shares Change (YoY) | 74.04% |
| Shares Change (QoQ) | 34.18% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,573 |
| FTD / Avg. Volume | 4.85% |
Short Selling Information
The latest short interest is 198.76K, so 5.34% of the outstanding
shares have been sold short.
| Short Interest | 198.76K |
| Short % of Shares Out | 5.34% |
| Short % of Float | 5.35% |
| Short Ratio (days to cover) | 8.95 |
Valuation Ratios
The PE ratio is -74.15 and the forward
PE ratio is -2.64.
BioLineRx's PEG ratio is
0.84.
| PE Ratio | -74.15 |
| Forward PE | -2.64 |
| PS Ratio | 23.63 |
| Forward PS | 0.8 |
| PB Ratio | 50.79 |
| P/FCF Ratio | -15.56 |
| PEG Ratio | 0.84 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for BioLineRx.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76,
with a Debt / Equity ratio of 1.12.
| Current Ratio | 1.76 |
| Quick Ratio | 1.56 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | -0.34 |
| Interest Coverage | -2.25 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,033,571.43 |
| Profits Per Employee | $-329,321.43 |
| Employee Count | 28 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -87.44% in the
last 52 weeks. The beta is 0.86, so BioLineRx's
price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -87.44% |
| 50-Day Moving Average | 3.08 |
| 200-Day Moving Average | 12.48 |
| Relative Strength Index (RSI) | 47.94 |
| Average Volume (20 Days) | 32,445 |
Income Statement
In the last 12 months, BioLineRx had revenue of 28.94M
and earned -9.22M
in profits. Earnings per share was -0.12.
| Revenue | 28.94M |
| Gross Profit | 19.68M |
| Operating Income | -20.41M |
| Net Income | -9.22M |
| EBITDA | 3.92M |
| EBIT | -147K |
| Earnings Per Share (EPS) | -0.12 |
Full Income StatementBalance Sheet
The company has 10.44M in cash and 15.04M in
debt, giving a net cash position of -4.6M.
| Cash & Cash Equivalents | 10.44M |
| Total Debt | 15.04M |
| Net Cash | -4.6M |
| Retained Earnings | -399.83M |
| Total Assets | 38.91M |
| Working Capital | 11.7M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -43.87M
and capital expenditures -54K, giving a free cash flow of -43.93M.
| Operating Cash Flow | -43.87M |
| Capital Expenditures | -54K |
| Free Cash Flow | -43.93M |
| FCF Per Share | -0.04 |
Full Cash Flow StatementMargins
Gross margin is 67.99%, with operating and profit margins of -70.52% and -31.86%.
| Gross Margin | 67.99% |
| Operating Margin | -70.52% |
| Pretax Margin | -31.86% |
| Profit Margin | -31.86% |
| EBITDA Margin | 13.54% |
| EBIT Margin | -70.52% |
| FCF Margin | -151.79% |
